TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02363413

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IniVAH
Description: Initiation of the NIV during a 3 days hospitalization as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IniVAD
Description: Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
Study: NCT01510795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
Study: NCT03396315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
Study: NCT02637401

Intervention type: BEHAVIORAL
Intervention: Dialectical Behaviour Therapy
Study: NCT01494155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
Study: NCT01080469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 1 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 1 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT00494052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart (Web-Based Decision Aid)
Description: Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Education Session
Description: A physician education session will be included in the program.
Study: NCT00644410

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stromal cell
Description: Mesenchymal stromal cells 20 - 40 mill.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12 injection with 0.2 ml saline
Study: NCT00879346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 160mg oral single dose (4 x 40mg tablets)
Study: NCT00381732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
Study: NCT05189301

Intervention type: DIAGNOSTIC_TEST
Intervention: first pass study
Description: Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)

Intervention type: DIAGNOSTIC_TEST
Intervention: first pass study
Description: Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)

Intervention type: DIAGNOSTIC_TEST
Intervention: first pass study
Description: Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise testing
Description: to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise testing
Description: to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise testing
Description: to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
Study: NCT01494155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton or Photon Radiation Therapy
Description: Daily, beginning Week 2 for 5 consecutive days
Study: NCT00215540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant 175 mg/kg
Description: Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant 90 mg/kg
Description: Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
Study: NCT00714922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK
Description: Laser refractive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBK
Description: Laser refractive surgery
Study: NCT03356730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months.
Study: NCT00246337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to match assigned treatment arm; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 25 mg; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 50 mg; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 100 mg; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 200 mg; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 300 mg; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 400 mg; one orally-administered dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 600 mg; one orally-administered dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: Rizatriptan 10 mg; one orally-administered dose
Study: NCT03270514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Study: NCT03831984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,09% Bromfenac
Description: topical 0,09% Bromfenac, one drop twice daily 3 days before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,1% sodium hyaluronate
Description: topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
Study: NCT04411602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 plasma
Description: To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
Study: NCT01253863

Intervention type: OTHER
Group type: OTHER
Intervention: exploration
Description: exploration of wound for determining damaged tissue
Study: NCT04642963

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac Radiosurgery
Description: Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
Study: NCT01226511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01840384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and Lactose
Study: NCT03077984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chinese medicine treatment
Description: The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
Study: NCT03566459

Intervention type: OTHER
Intervention: CBOC offering Tele-MOUD to Veterans
Description: CBOC offering medications for opioid use disorder (MOUD) using telemedicine

Intervention type: OTHER
Intervention: CBOC not offering Tele-MOUD to Veterans
Description: CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
Study: NCT02850822

Intervention type: DRUG
Intervention: Demethylation drug
Description: Demethylation drug,such as Decitabine

Intervention type: DRUG
Intervention: Chemotherapy regimen
Description: Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
Study: NCT04021927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring Phototherapy
Description: The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
Study: NCT03047278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Blood Samples
Description: Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Blood Samples
Description: Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Blood Samples
Description: Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Urine Samples
Description: Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Urine Samples
Description: Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Urine Samples
Description: Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
Study: NCT04259931

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiome analysis
Description: gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiome analysis
Description: gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
Study: NCT03047278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300 mg
Description: All patients were treated with oral single dose of gabapentin 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: All patients were treated with oral single dose of gabapentin 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: All patients were treated with oral single dose of gabapentin 300 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride 10 mg
Description: Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
Study: NCT01675050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 4 weeks of cyproheptadine or placebo with crossover to the other

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 4 weeks of cyproheptadine or placebo with crossover to the other

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugar pill
Description: 4 weeks of cyproheptadine or placebo with crossover to the other
Study: NCT02609321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Wound Infiltration
Description: Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
Study: NCT01675050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugar pill
Description: 4 weeks of cyproheptadine or placebo with crossover to the other
Study: NCT00411177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post-dilution on-line hemodiafiltration
Description: post-dilution on-line hemodiafiltration, 3 times a week 4 hours

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high flux hemodialysis
Description: High-flux hemodialysis, 3 times a week 4 hours
Study: NCT01725269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001
Description: All doses specified are the amount loaded into the I-neb AAD System nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001
Description: All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Study: NCT03646526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）
Description: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
Study: NCT01887418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QuickShot™ - 50 mg Treatment B
Description: QuickShot™ for the delivery of testosterone
Study: NCT01887418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QuickShot™ - 100 mg Treatment A
Description: QuickShot™ for the delivery of testosterone
Study: NCT03646526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）
Description: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
Study: NCT01887418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delatestryl 200 mg IM Treatment C
Description: Standard of care
Study: NCT02238691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mask ventilation with PEEP via a face mask device
Description: 15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask.
Study: NCT04787718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: 2.0 oz of raw, shelled, unsalted almonds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: an isocaloric amount of unsalted pretzels
Study: NCT03628456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: International Biophysics AffloVest
Description: High-frequency chest wall oscillation vest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hill-Rom Monarch
Description: High-frequency chest wall oscillation vest
Study: NCT03696602

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchial provocation test

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchial provocation test
Study: NCT00084747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study: NCT02728375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer game based rehabilitation protocol
Description: Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy protocol
Description: In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
Study: NCT02535962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus and Bifidobacterium lactis
Description: study product will be freeze dried and put into foil sachets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
Study: NCT04091412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
Study: NCT04561557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT103A cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.
Study: NCT03410108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablet
Study: NCT00853021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
Study: NCT00877188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: supervised combined aerobic and progressive resistance training for 12 weeks